HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PTHS
Pelthos Therapeutics Inc.
There isn't enough reported data to score PTHS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PTHS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PTHS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PTHS PE Valuation
PTHS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PTHS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PTHS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PTHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$25.39 | -$8.71 |
| Q2 2026 | -$28.65 | -$14.37 |
| Q1 2026 | -$27.41 | -$15.41 |
| Q4 2025 | -$23.04 | -$8.74 |
| Q3 2025 | -$16.68 | +$1.69 |
PTHS lost $25.39 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PTHS on profitability, with a higher operating margin.
PTHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +108% |
PTHS has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -63% | +145 points |
| Q2 2026 | -111% | N/A |
| Q1 2026 | -120% | N/A |
| Q4 2025 | -73% | N/A |
| Q3 2025 | -207% | N/A |
PTHS's operating margin was −63% last quarter, up 144 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with PTHS at down 187%.
PTHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.2M | +$10M |
| Q2 2026 | -$7.7M | -$7.2M |
| Q1 2026 | -$13.3M | -$12.7M |
| Q3 2025 | -$15.3M | -$15.1M |
| Q2 2025 | -$447.1K | +$2.5M |
| Q1 2025 | -$632.1K | +$1.4M |
| Q4 2024 | -$670.3K | -$313.5K |
PTHS has burned cash in almost every quarter: −$41M over the past year, against −$2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PTHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PTHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +323K shares |
| 1 year | +503% | +3.2M shares |
PTHS has 4M diluted shares, up 503% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | $75,000 |
| Q3 2024 | $75,000 |
| Q2 2024 | — |
| Q1 2024 | $91,512 |
| Q4 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PTHS Net Leverage
PTHS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PTHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.4 | Oversold |
| Stochastic | 1.5 | Oversold |
PTHS's weekly RSI is 20 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PTHS PE vs Healthcare Sector
PTHS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
PTHS has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus PTHS above 0 of 3.
PTHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 49% below |
| 20 week MA | $21.8 | 63% below |
| 50 week MA | $23.6 | 66% below |
PTHS is in a downtrend: it's below all three of its weekly moving averages, and 66% below its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over PTHS on returns for 2026, with the stronger performance.
PTHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $13.5 | $25.7 | +90% |
| 2026 YTD | $25.7 | $8.03 | -69% |
PTHS has finished every year since 2025 higher, and it's down 69% so far in 2026.